dbv - search results

If you're not happy with the results, please do another search
Viaskin Peanut

Private Law Firm to Investigate Claims on Behalf of Investors in DBV Technologies

It is unknown how this development will affect the ability of the company to eventually offer Viaskin Peanut as an FDA approved therapy.
Viaskin Peanut

FDA Issues Partial Hold on DBV Viaskin Peanut Patch Trial

Another delay for the long-awaited therapy.
Viaskin Patch

DBV Begins Phase 3 Study of Redesigned Viaskin Peanut Patch in Children Ages 4-7

Viaskin is testing a new version of their patch designed to address the FDA's concerns.
Viaskin Patch

DBV Announces Positive Topline Results from Phase 3 Trial of Viaskin Peanut in Peanut-Allergic...

Viaskin Peanut demonstrated a statistically significant treatment effect with 67.0% of subjects meeting the treatment responder criteria after 12 months.
Viaskin Patch

Viaskin Peanut Patch Therapy Delayed Further as DBV Readies Another Phase 3 Trial

The patch therapy remains in regulatory limbo.
Viaskin Patch

DBV Optimistic Viaskin Peanut “Patch” Therapy has Path to Approval After FDA Feedback

DBV, which also has Viaskin therapies for milk and egg allergies in their pipeline, is encouraged by FDA feedback after denial of their peanut therapy.
DBV Patch Closeup

DBV, Developers of Patch Therapies for Allergies to Peanuts, Milk and Eggs, to Lay...

The company announced they would be laying off 200 employees in Q1.
Viaskin-Patch-Delay

FDA Has Questions About Viaskin Peanut Efficacy, Delays Meeting with DBV Technologies

The company warned the FDA's target date for their decision on approval could be delayed.
Viaskin Peanut

DBV Technologies Reports Positive Three-Year, Long Term Data from Phase III Open-Label Extension Study...

Patients demonstrated durable, long-term clinical benefit with an additional two years of treatment.
Viaskin Peanut

DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment...

If approved, Viaskin Peanut would be the first and only epicutaneous immunotherapy indicated for this potentially life-threatening condition in children.